E ndothelial progenitor cells (EPCs) are thought to originate from the bone marrow, mobilize in response to ischemia, and home to sites of vascular injury. Despite uncertainty regarding their origin, phenotype, and therapeutic viability, there remains great interest in harnessing EPCs to promote vascular regeneration. Autologous bone marrow cells have been delivered to thousands of patients, on the premise that these populations contain functional EPCs, with conflicting results. 1 One potential explanation for the lack of consistent benefit is that bone marrow is not the origin of circulating EPCs. Indeed, although late-outgrowth endothelial cells can be readily isolated from cord and peripheral blood, 2,3 we have not been able to obtain endothelial cells from the culture of bone marrow. 3 These findings suggest that circulating EPCs arise from an alternative niche in the vessel wall.
Figure. The origin of endothelial progenitor cells.
A, Flow cytometric analysis of early-outgrowth cells, late-outgrowth endothelial cells, and vessel wall endothelial cells with antibodies to CD45, CD31, CD34, KDR, and CD146. Immunofluorescence staining for viable nuclei (DRAQ5, yellow), CD45 (blue), CD146 (magenta), and CD31 (green). Scale bar: 500 µm. B, Fluorescence in situ hybridization (FISH) for the X and Y chromosomes combined with CD31 staining of early-outgrowth cells (day 5), late-outgrowth endothelial cells (passage 1), and vessel wall endothelial cells (passage 1) in male patients with sex-mismatched bone marrow transplants. Representative images show Y chromosome (green), X chromosome (red), CD31 (yellow), and nuclei (DAPI, blue 
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contaminating hematopoietic cells commonly found by using this isolation protocol (Figure, D) . 2 These cells expressed CD45, were observed overlying the endothelial monolayer in 3-dimensional confocal z-stacks (Figure, E) , and were diminished from passage 1 to 3 (16.5±9.1% versus 1.8±0.9%; P<0.05), presumably because of their lack of proliferative capacity and inability to survive in endothelial-specific growth conditions. Short tandem repeat analysis of the sex-specific amelogenin gene locus was consistent with fluorescence in situ hybridization ( Figure, F) , confirming the XX genotype of early-outgrowth cells, the XY genotype of vessel wall endothelial cells, and that late-outgrowth endothelial cells were initially of mixed genotype with a declining fraction of contaminating XX cells between passages 1 and 3 (36.3±2.2% to 5.9±3.6%, P<0.05). Clonogenic colonies expanded from single cells were only obtained for late-outgrowth endothelial cells (4/5 participants, 8.8±4.0% efficiency) (Figure, G) . All clones expressed CD31 and were entirely XY in genotype.
Although our study includes a small number of participants, we have systematically studied the origin of EPCs in people with sex-mismatched bone marrow transplantation by using 2 distinct but complementary methods. Although endothelial cells can be obtained from a circulating progenitor and are capable of clonal expansion, these cells do not share the genotype of the transplanted bone marrow. We conclude that EPCs in circulation do not originate from the bone marrow.
Our findings contrast those of Lin and colleagues. 4 They recognized that single-cell culture would be necessary to definitively address whether endothelial cells capable of clonal expansion derive from bone marrow. These methods were used in our analysis demonstrating that all clones formed from single cells were derived from the recipient rather than from donor bone marrow. Our findings were internally consistent and clear, and in agreement with recent evidence showing that endogenous neovascularization in the heart is driven by tissue-resident EPCs without a direct contribution from bone marrow cells. 5 This represents a paradigm shift that requires a reevaluation of our approach to harness EPCs for therapeutic vascular regeneration.
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Data sharing: Data and supporting materials can be made available upon request from the corresponding author. Figure Continued. (white arrows) and CD31-positive cells with an XY genotype (yellow arrows) are shown. Scale bar: 20 μm. *P<0.001, one-way ANOVA. Genotype of early-outgrowth cells, late-outgrowth endothelial cells, and vessel wall endothelial cells with (C) and without (D) CD31 expression. E, Immunofluorescence for CD45 (blue) and CD31 (yellow) in late-outgrowth endothelial cells. Scale bar: 50 μm. F, Short tandem repeat analysis for the sex-specific locus, amelogenin. The proportion of cells with XX and XY genotype was calculated from polymerase chain reaction products of 104 and 110 base pairs corresponding to the X and Y chromosomes, respectively. *P<0.05, one-way ANOVA. G, Images showing expansion of a colony of late-outgrowth endothelial cells from a single endothelial progenitor cell of recipient origin (XY genotype). Y chromosome (green), X chromosome (red), CD31 (yellow), and nuclei (DAPI, blue). Scale bar: 100 μm. DAPI indicates 4′,6-diamidino-2-phenylindole; and STR, short tandem repeat.
